StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultAug 13, 2026, 04:23 PM

Fortress Biotech Q2 Revenue Up 14% to $18.7M; Net Loss $(2.5)M

AI Summary

Fortress Biotech reported its second quarter 2026 financial results, with total net revenue increasing 14% to $18.7 million compared to the prior year. The company posted a consolidated net loss attributable to common stockholders of $(2.5) million for the quarter. Key corporate highlights included Crystalys Therapeutics securing $130 million in Series B financing for dotinurad, and Journey Medical expanding payer access for Emrosi® to over 150 million commercial lives. Fortress also noted a strong cash position of $196.6 million as of June 30, 2026, following the ZYCUBO® PRV sale in Q1.

Key Highlights

  • Total net revenue increased 14% to $18.7 million for Q2 2026.
  • Consolidated net loss attributable to common stockholders was $(2.5) million for Q2 2026.
  • Consolidated cash and cash equivalents totaled $196.6 million as of June 30, 2026.
  • Journey Medical's Emrosi® expanded payer access to over 150 million commercial lives.
  • Crystalys Therapeutics announced $130 million Series B financing for dotinurad development.
  • AstraZeneca reported anselamimab improved survival by 62% in a subgroup analysis.
  • Consolidated R&D expenses decreased to $0.8 million for Q2 2026 from $8.1 million in Q2 2025.
  • Consolidated SG&A costs decreased to $20.8 million for Q2 2026 from $38.8 million in Q2 2025.